Showing results (501-510 of 2,398) with videos related to

Sort By:
Pageof 240
Breast Cancer (Tokyo, Japan)|January 3, 2025
Impact of breast size and composition on the accuracy of mammography and ultrasonography in breast cancer screeningAkira Nakamura, Koji Ohnuki, Haruka Takahashi, et al.
Breast Cancer (Tokyo, Japan)|August 27, 2024
Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscapeHetvi Ganatra, Joecelyn Kirani Tan, Ana Simmons, et al.
Breast Cancer (Tokyo, Japan)|November 15, 2024
Comparative assessment of breast volume using a smartphone device versus MRIAnnika S Behrens, Hanna Huebner, Lothar Häberle, et al.
Breast Cancer (Tokyo, Japan)|July 9, 2024
Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-portFulvio Pinelli, Francesco Barbani, Barbara Defilippo, et al.
Breast Cancer (Tokyo, Japan)|July 8, 2024
Development and validation of a neoadjuvant chemotherapy pathological complete remission model based on Reg IV expression in breast cancer tissues: a clinical retrospective studyJiao-Fei Wei, Fan Li, Jia-Wen Lin, et al.
Breast Cancer (Tokyo, Japan)|July 17, 2024
Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancerAkio Shibata, Nobuko Tamura, Keiichi Kinowaki, et al.
Breast Cancer (Tokyo, Japan)|July 13, 2024
High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probandsReiko Yoshida, Tomoko Kaneyasu, Arisa Ueki, et al.
Breast Cancer (Tokyo, Japan)|July 17, 2024
Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriersMari Hosonaga, Eri Habano, Hiromi Arakawa, et al.
Breast Cancer (Tokyo, Japan)|August 8, 2024
Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC)Masaki Nakamura, Takeshi Fujisawa, Hidekazu Oyoshi, et al.
Breast Cancer (Tokyo, Japan)|August 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabineRui Kitadai, Tatsunori Shimoi, Shu Yazaki, et al.
Pageof 240